Tejaswini Kulkarni MD
Critical Care Medicine, Interstitial Lung Diseases, Occupational & Environmental Lung Disease
Associate Professor Director, Interstitial Lung Disease Program
Join to View Full Profile
1717 6th Ave SBirmingham, AL 35233
Phone+1 800-822-8816
Dr. Kulkarni is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Tejaswini Kulkarni is a pulmonologist based in Birmingham, AL, with subspecialties in Critical Care Medicine, Interstitial Lung Diseases, and Occupational & Environmental Lung Disease. She completed her fellowship in Pulmonary Disease and Critical Care Medicine at the University of Alabama Medical Center and her residency in Internal Medicine at Detroit Medical Center/Wayne State University. She is an Associate Professor at the University of Alabama Hospital and has expertise in interstitial lung diseases, particularly those associated with connective tissue diseases and idiopathic pulmonary fibrosis. Dr. Kulkarni has authored several publications in reputable journals on topics related to pulmonary fibrosis. Additionally, she is currently principal investigator/ co-investigator on clinical trials studying new therapeutics for pulmonary fibrosis.
Education & Training
University of Alabama Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2013 - 2016
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 2010 - 2013
Bangalore Medical CollegeClass of 2008
Certifications & Licensure
AL State Medical License 2013 - 2025
MI State Medical License 2010 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis Start of enrollment: 2023 May 15
Roles: Contact
Publications & Presentations
PubMed
- TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity.Huachun Cui, Sami Banerjee, Na Xie, Musaddique Hussain, Ashish Jaiswal
Nature Communications. 2025-02-19 - "Breathing Through the Years": A Call for Combating Breathlessness, Frailty, and Sarcopenia in Older Adults.Tejaswini Kulkarni, Merry Lynn McDonald
Chest. 2024-12-01 - Persistence of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis: A Pulmonary Fibrosis Foundation Patient Registry Study.Tejaswini Kulkarni, Kevin Flaherty, Sachin Gupta, Yi-Hsuan Tu, Amy Hajari Case
Annals of the American Thoracic Society. 2024-10-15
Authored Content
- An Update in Progressive Pulmonary FibrosisOctober 2022
Press Mentions
Pulmonary and Primary Care Experts Share Clinician Toolkit on Rare Disease Day to Raise Awareness for Interstitial Lung DiseaseFebruary 28th, 2023- Pulmonary and Primary Care Experts Share Research on Delays to Diagnosis in Complex Lung DiseasesSeptember 19th, 2022
- Autoantibody Reduction Regimen Improves Lungs, Survival: StudyDecember 14th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
